C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 116 filers reported holding C4 THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $598,193 | -19.4% | 321,609 | +19.2% | 0.00% | – |
| Q2 2023 | $741,956 | +45.3% | 269,802 | +65.9% | 0.00% | – |
| Q1 2023 | $510,721 | -68.0% | 162,650 | -39.8% | 0.00% | -100.0% |
| Q4 2022 | $1,594,298 | -42.7% | 270,220 | -14.8% | 0.00% | 0.0% |
| Q3 2022 | $2,780,000 | -2.3% | 317,045 | -15.9% | 0.00% | 0.0% |
| Q2 2022 | $2,844,000 | -64.4% | 377,186 | +14.4% | 0.00% | -66.7% |
| Q1 2022 | $7,995,000 | -27.6% | 329,578 | -3.9% | 0.00% | 0.0% |
| Q4 2021 | $11,038,000 | -40.8% | 342,798 | -17.9% | 0.00% | -50.0% |
| Q3 2021 | $18,647,000 | +22.8% | 417,353 | +4.0% | 0.01% | +20.0% |
| Q2 2021 | $15,188,000 | +56.4% | 401,373 | +52.9% | 0.01% | +66.7% |
| Q1 2021 | $9,708,000 | +191.0% | 262,438 | +160.6% | 0.00% | +200.0% |
| Q4 2020 | $3,336,000 | – | 100,716 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $14,402,000 | 1.72% |
| Soleus Capital Management, L.P. | 1,441,513 | $12,642,000 | 1.72% |
| Nextech Invest Ltd. | 375,857 | $3,296,000 | 1.06% |
| RTW INVESTMENTS, LP | 2,819,472 | $24,727,000 | 0.57% |
| ArrowMark Colorado Holdings LLC | 5,091,975 | $44,657,000 | 0.55% |
| WASATCH ADVISORS LP | 5,934,476 | $52,045,000 | 0.36% |
| HARBOR CAPITAL ADVISORS, INC. | 25,470 | $223,000 | 0.20% |
| Perceptive Advisors | 766,231 | $6,720,000 | 0.20% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 606,721 | $5,321,000 | 0.08% |
| Virtus ETF Advisers LLC | 19,305 | $169,000 | 0.07% |